Cargando…

Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema

Breast cancer-related lymphedema (BCRL) occurs in a significant number of breast cancer survivors as a consequence of the axillary lymphatics' impairment after therapy (mainly axillary surgery and irradiation). Despite the recent achievements in the clinical management of these patients, BCRL i...

Descripción completa

Detalles Bibliográficos
Autores principales: Invernizzi, Marco, Lopez, Gianluca, Michelotti, Anna, Venetis, Konstantinos, Sajjadi, Elham, De Mattos-Arruda, Leticia, Ghidini, Michele, Runza, Letterio, de Sire, Alessandro, Boldorini, Renzo, Fusco, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142240/
https://www.ncbi.nlm.nih.gov/pubmed/32300557
http://dx.doi.org/10.3389/fonc.2020.00422
_version_ 1783519337317924864
author Invernizzi, Marco
Lopez, Gianluca
Michelotti, Anna
Venetis, Konstantinos
Sajjadi, Elham
De Mattos-Arruda, Leticia
Ghidini, Michele
Runza, Letterio
de Sire, Alessandro
Boldorini, Renzo
Fusco, Nicola
author_facet Invernizzi, Marco
Lopez, Gianluca
Michelotti, Anna
Venetis, Konstantinos
Sajjadi, Elham
De Mattos-Arruda, Leticia
Ghidini, Michele
Runza, Letterio
de Sire, Alessandro
Boldorini, Renzo
Fusco, Nicola
author_sort Invernizzi, Marco
collection PubMed
description Breast cancer-related lymphedema (BCRL) occurs in a significant number of breast cancer survivors as a consequence of the axillary lymphatics' impairment after therapy (mainly axillary surgery and irradiation). Despite the recent achievements in the clinical management of these patients, BCRL is often diagnosed at its occurrence. In most cases, it remains a progressive and irreversible condition, with dramatic consequences in terms of quality of life and on sanitary costs. There are still no validated pre-surgical strategies to identify individuals that harbor an increased risk of BCRL. However, clinical, therapeutic, and tumor-specific traits are recurrent in these patients. Over the past few years, many studies have unraveled the complexity of the molecular and transcriptional events leading to the lymphatic system ontogenesis. Additionally, molecular insights are coming from the study of the germline alterations involved at variable levels in BCRL models. Regrettably, there is a substantial lack of predictive biomarkers for BCRL, given that our knowledge of its molecular milieu remains extremely puzzled. The purposes of this review were (i) to outline the biology underpinning the ontogenesis of the lymphatic system; (ii) to assess the current state of knowledge of the molecular alterations that can be involved in BCRL pathogenesis and progression; (iii) to discuss the present and short-term future perspectives in biomarker-based patients' risk stratification; and (iv) to provide practical information that can be employed to improve the quality of life of these patients.
format Online
Article
Text
id pubmed-7142240
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-71422402020-04-16 Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema Invernizzi, Marco Lopez, Gianluca Michelotti, Anna Venetis, Konstantinos Sajjadi, Elham De Mattos-Arruda, Leticia Ghidini, Michele Runza, Letterio de Sire, Alessandro Boldorini, Renzo Fusco, Nicola Front Oncol Oncology Breast cancer-related lymphedema (BCRL) occurs in a significant number of breast cancer survivors as a consequence of the axillary lymphatics' impairment after therapy (mainly axillary surgery and irradiation). Despite the recent achievements in the clinical management of these patients, BCRL is often diagnosed at its occurrence. In most cases, it remains a progressive and irreversible condition, with dramatic consequences in terms of quality of life and on sanitary costs. There are still no validated pre-surgical strategies to identify individuals that harbor an increased risk of BCRL. However, clinical, therapeutic, and tumor-specific traits are recurrent in these patients. Over the past few years, many studies have unraveled the complexity of the molecular and transcriptional events leading to the lymphatic system ontogenesis. Additionally, molecular insights are coming from the study of the germline alterations involved at variable levels in BCRL models. Regrettably, there is a substantial lack of predictive biomarkers for BCRL, given that our knowledge of its molecular milieu remains extremely puzzled. The purposes of this review were (i) to outline the biology underpinning the ontogenesis of the lymphatic system; (ii) to assess the current state of knowledge of the molecular alterations that can be involved in BCRL pathogenesis and progression; (iii) to discuss the present and short-term future perspectives in biomarker-based patients' risk stratification; and (iv) to provide practical information that can be employed to improve the quality of life of these patients. Frontiers Media S.A. 2020-04-02 /pmc/articles/PMC7142240/ /pubmed/32300557 http://dx.doi.org/10.3389/fonc.2020.00422 Text en Copyright © 2020 Invernizzi, Lopez, Michelotti, Venetis, Sajjadi, De Mattos-Arruda, Ghidini, Runza, de Sire, Boldorini and Fusco. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Invernizzi, Marco
Lopez, Gianluca
Michelotti, Anna
Venetis, Konstantinos
Sajjadi, Elham
De Mattos-Arruda, Leticia
Ghidini, Michele
Runza, Letterio
de Sire, Alessandro
Boldorini, Renzo
Fusco, Nicola
Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema
title Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema
title_full Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema
title_fullStr Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema
title_full_unstemmed Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema
title_short Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema
title_sort integrating biological advances into the clinical management of breast cancer related lymphedema
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142240/
https://www.ncbi.nlm.nih.gov/pubmed/32300557
http://dx.doi.org/10.3389/fonc.2020.00422
work_keys_str_mv AT invernizzimarco integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema
AT lopezgianluca integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema
AT michelottianna integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema
AT venetiskonstantinos integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema
AT sajjadielham integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema
AT demattosarrudaleticia integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema
AT ghidinimichele integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema
AT runzaletterio integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema
AT desirealessandro integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema
AT boldorinirenzo integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema
AT fusconicola integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema